Skip header and navigation

Refine By

78 records – page 1 of 8.

Major depressive disorder treatment guidelines in America and Europe.

https://arctichealth.org/en/permalink/ahliterature144294
Source
J Clin Psychiatry. 2010;71 Suppl E1:e04
Publication Type
Article
Conference/Meeting Material
Date
2010
Author
Jonathan R T Davidson
Author Affiliation
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA. david011@mc.duke.edu
Source
J Clin Psychiatry. 2010;71 Suppl E1:e04
Date
2010
Language
English
Publication Type
Article
Conference/Meeting Material
Keywords
Antidepressive Agents - adverse effects - therapeutic use
Canada
Combined Modality Therapy
Comorbidity
Cross-Cultural Comparison
Depressive Disorder, Major - diagnosis - drug therapy - psychology
Electroconvulsive Therapy
Europe
Evidence-Based Medicine
Humans
Practice Guidelines as Topic
Psychotherapy
Recurrence - prevention & control
United States
Abstract
The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission. While the guidelines are all evidence-based, certain factors can influence differences in specific recommendations, such as the consensus group's composition, underlying mandates, and cultural attitudes. The similarities and differences among 6 sets of guidelines from Europe and the Americas published in the past decade are reviewed here (American Psychiatric Association, British Association for Psychopharmacology, Canadian Network for Mood and Anxiety Treatments, National Institute for Health and Clinical Excellence, Texas Medication Algorithm Project, and World Federation of Societies of Biological Psychiatry). In the guidelines, mild depression has the most variance in treatment recommendations; some, but not all, guidelines suggest that it may resolve with exercise or watchful waiting, but psychotherapy or antidepressants could be used if initial efforts fail. Moderate and severe major depression carry broadly similar recommendations among the guidelines. First-line treatment recommendations for moderate major depressive disorder include antidepressant monotherapy, psychotherapy, and the combination of both. Severe depression may require the combination of an antidepressant and an antipsychotic, electroconvulsive therapy, or the combination of an antidepressant and psychotherapy. Benzodiazepines play a very limited role in the treatment of depression; if the patient has catatonic depression, acutely suicidal depression, or depression with symptoms of anxiety, agitation, or insomnia, benzodiazepines are recommended by some guidelines for short-term treatment only.
PubMed ID
20371031 View in PubMed
Less detail

Towards equity in Aboriginal health: an overview of factors impacting the delivery of health services to Aboriginal peoples of Canada

https://arctichealth.org/en/permalink/ahliterature286414
Source
Pages 388-393 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Publication Type
Conference/Meeting Material
Article
Date
2010
  1 document  
Author
Dennis Ballard
Catherine Cook
Annette Alix-Roussin
Kimberly Gray
Author Affiliation
Winnipeg Regional Health Authority, Winnipeg, Canada
Source
Pages 388-393 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Date
2010
Language
English
Geographic Location
Canada
Publication Type
Conference/Meeting Material
Article
Digital File Format
Text - PDF
Physical Holding
University of Alaska Anchorage
Keywords
Aboriginal
First Nations
Inuit
Canada
Health care
Abstract
Objectives: This paper will discuss the impact historic legislation and policies have had on the delivery of health services to Aboriginal peoples and look at the efforts that are underway to amend the legislation and policies in order to provide health care and services to Aboriginal peoples. Methods: Literature re view. Results: The present health services delivered to Aboriginal peoples are a direct result of historic legislation and policies that directly or indirectly produced jurisdictional barriers encountered by Aboriginal peoples and health service providers when seeking these services. Conclusions: Today there are health care providers that are addressing these jurisdictional barriers in an effort to adequately provide Aboriginal peoples with health services when required.
Documents
Less detail

National Strategy to Prevent Abuse in Inuit Communities and National Inuit Residential Schools Healing Strategy

https://arctichealth.org/en/permalink/ahliterature286419
Source
Page 439 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Publication Type
Conference/Meeting Material
Date
2010
  1 document  
Author
Tagornak D.
Author Affiliation
Pauktuutit Inuit Women of Canada
Source
Page 439 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Date
2010
Language
English
Geographic Location
Canada
Publication Type
Conference/Meeting Material
Digital File Format
Text - PDF
Physical Holding
University of Alaska Anchorage
Keywords
Inuit
Abuse
Notes
Part of Abstracts: Oral presentations. Chapter 10. Mental Health and Wellness.
Documents
Less detail

A content analysis of websites featuring Inuit health information

https://arctichealth.org/en/permalink/ahliterature286463
Source
Page 531 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Publication Type
Conference/Meeting Material
Date
2010
  1 document  
Author
C. Fletcher
C. Alton
C.Y. Jean
Author Affiliation
University of Alberta
Source
Page 531 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Date
2010
Language
English
Geographic Location
Canada
Publication Type
Conference/Meeting Material
Digital File Format
Text - PDF
Physical Holding
University of Alaska Anchorage
Keywords
Health
Information
Inuit
Literature
Notes
Part of Abstracts: Oral presentations. Chapter 13. Building Health Services Resources and Research Capacity.
Documents
Less detail

Introduction to the Academic Symposium to Evaluate Evidence Regarding the Efficacy of Trauma Systems.

https://arctichealth.org/en/permalink/ahliterature200773
Source
J Trauma. 1999 Sep;47(3 Suppl):S3-7
Publication Type
Conference/Meeting Material
Article
Date
Sep-1999
Author
R J Mullins
N C Mann
Author Affiliation
Department of Surgery, Oregon Health Sciences University, School of Medicine, Portland 97201-3098, USA. mullinsr@ohsu.edu
Source
J Trauma. 1999 Sep;47(3 Suppl):S3-7
Date
Sep-1999
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Canada
Evidence-Based Medicine
Humans
Outcome Assessment (Health Care)
Practice Guidelines as Topic
Program Evaluation
Regional Medical Programs - standards
Trauma Centers - organization & administration
United States
PubMed ID
10496603 View in PubMed
Less detail

Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

https://arctichealth.org/en/permalink/ahliterature207336
Source
CMAJ. 1997 Nov 1;157(9):1245-54
Publication Type
Conference/Meeting Material
Article
Date
Nov-1-1997
Author
E. Rey
J. LeLorier
E. Burgess
I R Lange
L. Leduc
Author Affiliation
Department of Medicine, University of Montreal, Que.
Source
CMAJ. 1997 Nov 1;157(9):1245-54
Date
Nov-1-1997
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Antihypertensive Agents - classification - therapeutic use
Blood Pressure - drug effects
Canada
Diastole
Evidence-Based Medicine
Female
Humans
Hypertension - diagnosis - drug therapy
Pregnancy
Pregnancy Complications, Cardiovascular - diagnosis - drug therapy
Pregnancy outcome
Severity of Illness Index
Systole
Treatment Outcome
Abstract
To provide Canadian physicians with evidence-based guidelines for the pharmacologic treatment of hypertensive disorders in pregnancy.
No medication, or treatment with antihypertensive or anticonvulsant drugs.
Prevention of maternal complications, and prevention of perinatal complications and death.
Pertinent articles published from 1962 to September 1996 retrieved from the Pregnancy and Childbirth Module of the Cochrane Database of Systematic Reviews and from MEDLINE; additional articles retrieved through a manual search of bibliographies; and expert opinion. Recommendations were graded according to levels of evidence.
Maternal and fetal well-being were equally valued, with the belief that treatment side effects should be minimized.
Reduction in the rate of adverse perinatal outcomes, including death. Potential side effects of antihypertensive drugs include placental hypoperfusion, intrauterine growth retardation and long-term effects on the infant.
A systolic blood pressure greater than 169 mm Hg or a diastolic pressure greater than 109 mm Hg in a pregnant woman should be considered an emergency and pharmacologic treatment with hydralazine, labetalol or nifedipine started. Otherwise, the thresholds at which to start antihypertensive treatment are a systolic pressure of 140 mm Hg or a diastolic pressure of 90 mm Hg in women with gestational hypertension without proteinuria or pre-existing hypertension before 28 weeks' gestation, those with gestational hypertension and proteinuria or symptoms at any time during the pregnancy, those with pre-existing hypertension and underlying conditions or target-organ damage, and those with pre-existing hypertension and superimposed gestational hypertension. The thresholds in other circumstances are a systolic pressure of 150 mm Hg or a diastolic pressure of 95 mm Hg. For nonsevere hypertension, methyldopa is the first-line drug; labetalol, pindolol, oxprenolol and nifedipine are second-line drugs. Fetal distress attributed to placental hypoperfusion is rare, and long-term effects on the infant are unknown. Magnesium sulfate is recommended for the prevention and treatment of seizures.
The guidelines are more precise but compatible with those from the US and Australia.
Notes
Cites: Am J Obstet Gynecol. 1984 Dec 1;150(7):831-56507509
Cites: Arch Dis Child. 1984 Nov;59(11):1061-36391390
Cites: Br Med J (Clin Res Ed). 1985 Jan 5;290(6461):17-233917318
Cites: Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):563-63929874
Cites: Obstet Gynecol. 1985 Nov;66(5):634-83903581
Cites: Acta Obstet Gynecol Scand. 1985;64(6):505-103904322
Cites: Obstet Gynecol. 1986 Feb;67(2):197-2053945429
Cites: Aust N Z J Obstet Gynaecol. 1986 Feb;26(1):26-93524548
Cites: Br J Obstet Gynaecol. 1986 Jun;93(6):543-73524664
Cites: Int J Gynaecol Obstet. 1986 Feb;24(1):3-72874067
Cites: Obstet Gynecol. 1987 Sep;70(3 Pt 1):323-73627579
Cites: Obstet Gynecol. 1987 Sep;70(3 Pt 1):328-333306494
Cites: Br Med J (Clin Res Ed). 1988 Apr 30;296(6631):1209-103133014
Cites: Am J Obstet Gynecol. 1988 Aug;159(2):308-93407684
Cites: Am J Obstet Gynecol. 1988 Sep;159(3):650-43421264
Cites: Arch Mal Coeur Vaiss. 1988 Jun;81 Spec No:137-403142396
Cites: Br J Obstet Gynaecol. 1988 Sep;95(9):868-763056503
Cites: Chest. 1989 Feb;95(2 Suppl):2S-4S2914516
Cites: Br J Obstet Gynaecol. 1989 Jan;96(1):38-432647130
Cites: Am J Obstet Gynecol. 1989 Jul;161(1):35-62750819
Cites: S Afr Med J. 1989 Sep 16;76(6):248-502781421
Cites: Am J Perinatol. 1989 Oct;6(4):437-412789542
Cites: Am J Obstet Gynecol. 1990 Mar;162(3):788-922316590
Cites: Br J Obstet Gynaecol. 1990 Feb;97(2):104-92317464
Cites: Br J Obstet Gynaecol. 1990 Feb;97(2):110-72180472
Cites: Am J Obstet Gynecol. 1990 Apr;162(4):960-6; discussion 966-72183619
Cites: Am J Obstet Gynecol. 1990 May;162(5):1141-52288560
Cites: Am J Perinatol. 1990 Jul;7(3):285-62372339
Cites: BMJ. 1990 Sep 22;301(6752):587-92242456
Cites: Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1844-82256493
Cites: Obstet Gynecol. 1991 Mar;77(3):331-71992393
Cites: Med J Aust. 1991 Mar 18;154(6):378-822000050
Cites: Obstet Gynecol. 1991 Jul;78(1):128-352047053
Cites: Br J Obstet Gynaecol. 1991 May;98(5):453-92059591
Cites: Teratology. 1991 Jun;43(6):543-61882342
Cites: Am J Obstet Gynecol. 1991 Oct;165(4 Pt 1):907-131951552
Cites: J Clin Ultrasound. 1992 Feb;20(2):115-91314260
Cites: Eur J Obstet Gynecol Reprod Biol. 1992 Jun 16;45(1):47-511618361
Cites: Obstet Gynecol. 1992 Sep;80(3 Pt 1):429-321495700
Cites: Obstet Gynecol. 1992 Nov;80(5):783-71407916
Cites: Am J Obstet Gynecol. 1992 Oct;167(4 Pt 1):879-841415419
Cites: Int J Gynaecol Obstet. 1993 Jan;40(1):39-438094349
Cites: Can J Anaesth. 1993 Apr;40(4):329-338485793
Cites: Am J Perinatol. 1993 May;10(3):233-88517903
Cites: Obstet Gynecol. 1993 Sep;82(3):375-98355937
Cites: Br J Obstet Gynaecol. 1993 Jul;100(7):623-88369243
Cites: Br J Obstet Gynaecol. 1993 Jul;100(7):692-38369257
Cites: Br J Obstet Gynaecol. 1993 Oct;100(10):959-618217985
Cites: Br J Obstet Gynaecol. 1994 Mar;101(3):262-38193107
Cites: Br J Obstet Gynaecol. 1994 May;101(5):409-138018612
Cites: Obstet Gynecol. 1994 Sep;84(3):354-98058230
Cites: Am J Obstet Gynecol. 1994 Sep;171(3):818-228092235
Cites: J Hosp Infect. 1994 Jul;27(3):161-67963456
Cites: N Engl J Med. 1995 Jul 27;333(4):201-57791836
Cites: N Engl J Med. 1995 Jul 27;333(4):250-17791843
Cites: Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):929-357573271
Cites: Am J Obstet Gynecol. 1996 Mar;174(3):823-88633650
Cites: CMAJ. 1997 Sep 15;157(6):715-259307560
Cites: CMAJ. 1997 Oct 1;157(7):907-199327800
Cites: Am J Obstet Gynecol. 1962 Oct 1;84:919-2913893680
Cites: Obstet Gynecol. 1962 Mar;19:355-814006267
Cites: Teratology. 1989 Oct;40(4):351-82814896
Cites: Am J Obstet Gynecol. 1964 Aug 1;89:891-714207556
Cites: Lancet. 1968 Aug 31;2(7566):488-904174507
Cites: Br J Obstet Gynaecol. 1975 Jul;82(7):572-71096930
Cites: Am J Obstet Gynecol. 1976 JUl 15;125(6):740-6937399
Cites: Lancet. 1976 Oct 9;2(7989):753-661439
Cites: Obstet Gynecol. 1977 Jun;49(6):675-80865730
Cites: Obstet Gynecol. 1979 Mar;53(3 Suppl):50S-55S424128
Cites: Br Med J (Clin Res Ed). 1981 Oct 24;283(6299):1077-96794766
Cites: Lancet. 1982 Mar 20;1(8273):647-96121965
Cites: Br J Clin Pharmacol. 1982;13(Suppl 2):375S-378S6125190
Cites: Obstet Gynecol. 1982 Oct;60(4):533-87121943
Cites: Clin Exp Hypertens B. 1982;1(2-3):371-837139977
Cites: Br J Obstet Gynaecol. 1982 Dec;89(12):1031-47171513
Cites: Lancet. 1983 Feb 26;1(8322):431-46131164
Cites: Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1927-306407638
Cites: Clin Exp Hypertens B. 1983;2(2):341-506872291
Cites: Am J Obstet Gynecol. 1984 May 15;149(2):171-36720794
Comment In: ACP J Club. 1998 May-Jun;128(3):63
PubMed ID
9361646 View in PubMed
Less detail

Complementary therapy and cancer: decision making by patients and their physicians setting a research agenda.

https://arctichealth.org/en/permalink/ahliterature183421
Source
Patient Educ Couns. 1999 Oct;38(2):87-92
Publication Type
Conference/Meeting Material
Article
Date
Oct-1999
Author
C P Herbert
M. Verhoef
M. White
M. O'Beirne
R. Doll
Author Affiliation
UBC Department of Family Practice, 5804 Fairview Avenue, Vancouver, B.C., Canada V6T 1Z3.
Source
Patient Educ Couns. 1999 Oct;38(2):87-92
Date
Oct-1999
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Canada
Communication
Complementary Therapies - standards
Decision Making
Evidence-Based Medicine
Health Priorities
Humans
Needs Assessment
Neoplasms - psychology - therapy
Outcome Assessment (Health Care)
Patient care team
Patient Participation - psychology
Patient Selection
Physician-Patient Relations
Physicians - psychology
Registries
Research Personnel - psychology
Abstract
An invitational meeting, entitled Complementary and Alternative Therapy: Decision Making by Cancer Patients and Their Physicians, brought together Canadian health care providers and researchers who had expertise in patient-physician communication with those who were knowledgeable about complementary therapy and cancer. The aim was to build on the existing knowledge base in both fields in order to determine the unanswered questions, the most important questions, and what methods can be applied for answering these questions. The interdisciplinary group employed a step-wise collaborative process to develop a suggested research agenda regarding decision making by physicians and their cancer patients regarding complementary therapy. The four themes identified are establishment of a registry for complementary therapy usage for cancer care; communication; outcomes measurement; and models of integration. It is hoped that these themes will be considered worthy of support by funding agencies and worthy of investigation by researchers.
PubMed ID
14528700 View in PubMed
Less detail

[About All-Russia Congress "Pediatric Cardiology 2002", Moscow, May 29-31, 2002].

https://arctichealth.org/en/permalink/ahliterature184113
Source
Kardiologiia. 2003;43(3):82-3
Publication Type
Conference/Meeting Material
Date
2003

Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

https://arctichealth.org/en/permalink/ahliterature165499
Source
Can J Cardiol. 2007 Jan;23(1):21-45
Publication Type
Conference/Meeting Material
Article
Date
Jan-2007
Author
J Malcom O Arnold
Jonathan G Howlett
Paul Dorian
Anique Ducharme
Nadia Giannetti
Haissam Haddad
George A Heckman
Andrew Ignaszewski
Debra Isaac
Philip Jong
Peter Liu
Elizabeth Mann
Robert S McKelvie
Gordon W Moe
John D Parker
Anna M Svendsen
Ross T Tsuyuki
Kelly O'Halloran
Heather J Ross
Vivek Rao
Errol J Sequeira
Michel White
Author Affiliation
University of Western Ontario, London, Canada. malcolm.arnold@lhsc.on.ca
Source
Can J Cardiol. 2007 Jan;23(1):21-45
Date
Jan-2007
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Acute Disease
Biological Markers
Canada
Cardiac Output, Low - diagnosis - prevention & control - therapy
Chronic Disease
Comorbidity
Evidence-Based Medicine
Health Priorities
Heart Failure - diagnosis - prevention & control - therapy
Humans
Natriuretic Peptide, Brain
Practice Guidelines as Topic
Risk factors
Abstract
Heart failure is common, yet it is difficult to treat. It presents in many different guises and circumstances in which therapy needs to be individualized. The Canadian Cardiovascular Society published a comprehensive set of recommendations in January 2006 on the diagnosis and management of heart failure, and the present update builds on those core recommendations. Based on feedback obtained through a national program of heart failure workshops during 2006, several topics were identified as priorities because of the challenges they pose to health care professionals. New evidence-based recommendations were developed using the structured approach for the review and assessment of evidence adopted and previously described by the Society. Specific recommendations and practical tips were written for the prevention of heart failure, the management of heart failure during intercurrent illness, the treatment of acute heart failure, and the current and future roles of biomarkers in heart failure care. Specific clinical questions that are addressed include: which patients should be identified as being at high risk of developing heart failure and which interventions should be used? What complications can occur in heart failure patients during an intercurrent illness, how should these patients be monitored and which medications may require a dose adjustment or discontinuation? What are the best therapeutic, both drug and nondrug, strategies for patients with acute heart failure? How can new biomarkers help in the treatment of heart failure, and when and how should BNP be measured in heart failure patients? The goals of the present update are to translate best evidence into practice, to apply clinical wisdom where evidence for specific strategies is weaker, and to aid physicians and other health care providers to optimally treat heart failure patients to result in a measurable impact on patient health and clinical outcomes in Canada.
Notes
Cites: JAMA. 1992 Jul 8;268(2):210-61608139
Cites: N Engl J Med. 1992 Sep 3;327(10):685-911463530
Cites: Lancet. 1992 Nov 14;340(8829):1173-81359258
Cites: Am J Cardiol. 1993 Jan 21;71(3):21A-28A8422000
Cites: J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A8376698
Cites: J Intern Med. 1994 Apr;235(4):329-348151264
Cites: Am Heart J. 1994 Sep;128(3):564-748074021
Cites: Circulation. 1994 Oct;90(4):1731-87923656
Cites: Int J Clin Pharmacol Res. 1998;18(3):121-89825268
Cites: Eur Heart J. 1998 Dec;19 Suppl P:P5-89886706
Cites: Int Psychogeriatr. 1998 Dec;10(4):421-339924835
Cites: BMJ. 1999 Feb 6;318(7180):368-729933201
Cites: Heart. 1999 Jan;81(1):25-3210220541
Cites: BMJ. 1999 May 22;318(7195):1400-210334754
Cites: Am Heart J. 1999 Aug;138(2 Pt 1):247-5310426835
Cites: Heart Fail Rev. 2004 Apr;9(2):107-1315516858
Cites: Circulation. 2004 Nov 2;110(18):2809-1615492322
Cites: Arch Intern Med. 2004 Nov 8;164(20):2247-5215534162
Cites: Circulation. 2004 Nov 9;110(19):3081-715520317
Cites: Eur J Heart Fail. 2004 Oct;6(6):761-815542414
Cites: Eur J Heart Fail. 2004 Dec;6(7):909-1615556053
Cites: Eur Heart J. 2005 Jan;26(1):11-715615794
Cites: Eur Heart J. 2005 Feb;26(3):215-2515642700
Cites: JAMA. 2005 Feb 2;293(5):572-8015687312
Cites: Circulation. 2005 Feb 8;111(5):583-9015699279
Cites: Eur Heart J. 2005 Feb;26(4):384-41615681577
Cites: Hypertension. 2005 Mar;45(3):412-815655115
Cites: Circulation. 2005 Mar 29;111(12):1487-9115781736
Cites: Heart Fail Rev. 2004 Jul;9(3):195-20115809817
Cites: J Am Geriatr Soc. 2005 Apr;53(4):695-915817019
Cites: Am J Cardiol. 2005 Apr 15;95(8):948-5415820160
Cites: JAMA. 2005 Apr 20;293(15):1900-515840865
Cites: Am Heart J. 2005 Feb;149(2):209-1615846257
Cites: Eur Heart J. 2005 Jun;26(11):1115-4015901669
Cites: Eur J Heart Fail. 2005 Jun;7(4):604-1115921801
Cites: BMJ. 2005 Jun 11;330(7504):137015947399
Cites: Am Heart J. 2005 Apr;149(4):744-5015990762
Cites: J Am Coll Cardiol. 2005 Jul 5;46(1):57-6415992636
Cites: CMAJ. 2005 Jul 5;173(1):40-515997043
Cites: Prog Cardiovasc Dis. 2005 Mar-Apr;47(5):320-3216003647
Cites: Am Heart J. 2005 Jul;150(1):46-5316084150
Cites: BMJ. 2000 Aug 12;321(7258):405-1210938048
Cites: Eur J Heart Fail. 2000 Sep;2(3):305-1310938493
Cites: J Am Coll Cardiol. 2001 Feb;37(2):379-8511216950
Cites: J Am Coll Cardiol. 2001 Feb;37(2):386-9111216951
Cites: Eur Heart J. 2001 Feb;22(3):228-3611161934
Cites: Circulation. 2001 Jan 23;103(3):369-7411157687
Cites: Clin Pharmacol Ther. 2001 Mar;69(3):89-9511240971
Cites: Eur J Heart Fail. 2001 Mar;3(2):225-3111246061
Cites: Am Heart J. 2001 Mar;141(3):439-4611231443
Cites: J Am Coll Cardiol. 2001 Mar 15;37(4):1042-811263606
Cites: Am J Med. 2001 Apr 1;110(5):378-8411286953
Cites: Arch Intern Med. 2001 Apr 9;161(7):996-100211295963
Cites: J Am Coll Cardiol. 2001 May;37(6):1677-8211345383
Cites: Eur J Clin Pharmacol. 2001 Apr;57(1):71-511372596
Cites: Circulation. 2001 Jun 5;103(22):2668-7311390335
Cites: J Am Coll Cardiol. 2001 Jun 1;37(7):1775-8011401110
Cites: J Am Coll Cardiol. 2001 Jun 1;37(7):1781-711401111
Cites: JAMA. 2001 Jul 25;286(4):421-611466120
Cites: JAMA. 2003 Jul 2;290(1):81-512837715
Cites: J Am Coll Cardiol. 2003 Jul 2;42(1):140-712849674
Cites: Heart. 2003 Aug;89(8):879-8112860863
Cites: Mayo Clin Proc. 2005 Aug;80(8):1029-3616092582
Cites: Circulation. 2005 Aug 23;112(8):1121-716103233
Cites: CMAJ. 2005 Aug 30;173(5):489-9516129869
Cites: Circulation. 2005 Sep 20;112(12):e154-23516160202
Cites: CMAJ. 2005 Sep 27;173(7):779-8816186585
Cites: Diabetes Care. 2005 Oct;28(10):2345-5116186261
Cites: Circulation. 2005 Oct 4;112(14):2163-816203929
Cites: Lancet. 2005 Oct 8;366(9493):1279-8916214598
Cites: J Clin Hypertens (Greenwich). 2005 Sep;7(9):520-8; quiz 529-3016227771
Cites: J Am Coll Cardiol. 2006 Sep 19;48(6):1198-20516979005
Cites: Eur Heart J. 2006 Oct;27(19):2338-4516963472
Cites: Ann Pharmacother. 2006 Oct;40(10):1797-80316954328
Cites: N Engl J Med. 2006 Oct 12;355(15):1551-6216980380
Cites: J Card Fail. 2006 Oct;12(8):664-7417045188
Cites: Eur Heart J. 2006 Nov;27(22):2725-3617000631
Cites: JAMA. 2006 Nov 8;296(18):2209-1617090767
Cites: N Engl J Med. 2006 Nov 16;355(20):2085-9817108343
Cites: N Engl J Med. 2006 Dec 7;355(23):2427-4317145742
Cites: Eur J Heart Fail. 2007 Mar;9(3):280-617027334
Cites: Int J Cardiol. 2007 May 2;117(3):296-30516901559
Cites: Am J Med. 2001 Sep;111(4):274-911566457
Cites: Hypertension. 2001 Sep;38(3):417-2311566915
Cites: J Am Coll Cardiol. 2001 Nov 1;38(5):1456-6211691523
Cites: Cardiol Clin. 2001 Nov;19(4):557-7111715177
Cites: Circulation. 2001 Dec 11;104(24):2996-300711739319
Cites: J Am Coll Cardiol. 2001 Dec;38(7):1934-4111738297
Cites: Chest. 2001 Dec;120(6):2047-5011742939
Cites: Cardiology. 2001;96(3-4):144-5411805381
Cites: Cardiology. 2001;96(3-4):155-6811805382
Cites: Cardiology. 2001;96(3-4):177-8211805384
Cites: Ann Emerg Med. 2002 Feb;39(2):131-811823766
Cites: Circulation. 2002 Feb 5;105(5):595-60111827925
Cites: Heart. 2002 Mar;87(3):229-3411847159
Cites: J Intern Med. 2001 Nov;250(5):422-811887977
Cites: Am J Cardiol. 2002 Mar 15;89(6):691-511897211
Cites: JAMA. 2002 Mar 27;287(12):1531-4011911755
Cites: JAMA. 2002 Mar 27;287(12):1541-711911756
Cites: Am J Med. 2002 Apr 15;112(6):437-4511959053
Cites: J Card Fail. 2002 Apr;8(2):79-8512016631
Cites: J Am Coll Cardiol. 2002 May 15;39(10):1623-912020489
Cites: Am Heart J. 2002 May;143(5):814-2012040342
Cites: Am J Cardiol. 2002 Jul 15;90(2):147-912106845
Cites: Eur Heart J. 1991 Mar;12(3):315-212040313
Cites: Circulation. 2004 Jun 29;109(25):3176-8115184280
Cites: Diabetes Care. 2004 Aug;27(8):1879-8415277411
Cites: J Card Fail. 2004 Aug;10(4):297-30315309695
Cites: Ital Heart J. 2004 Jun;5(6):441-915320569
Cites: Med Clin North Am. 2004 Sep;88(5):1273-9415331317
Cites: J Am Coll Cardiol. 2004 Sep 1;44(5):959-6615337204
Cites: Arch Intern Med. 2004 Sep 13;164(16):1729-3615364665
Cites: Circulation. 2004 Sep 14;110(11):1424-3015353499
Cites: J Am Coll Cardiol. 2004 Sep 15;44(6):1328-3315364340
Cites: J Am Coll Cardiol. 2004 Oct 6;44(7):1446-5315464326
Cites: J Card Fail. 2004 Oct;10(5):380-315470647
Cites: Am J Cardiol. 1974 Jul;34(1):29-344835750
Cites: Am J Med. 1981 Feb;70(2):234-97468610
Cites: Eur Heart J. 1985 Nov;6(11):954-84076205
Cites: Arch Intern Med. 1988 Feb;148(2):286-913341836
Cites: Arch Intern Med. 1988 Sep;148(9):2013-63046541
Cites: JAMA. 1989 Feb 10;261(6):884-82913385
Cites: Eur Heart J. 1989 Jul;10(7):647-562788575
Cites: Lancet. 1990 Jan 6;335(8680):29-311967337
Cites: Angiology. 1990 Oct;41(10):862-82221464
Cites: Ann Intern Med. 1990 Dec 15;113(12):941-82240918
Cites: N Engl J Med. 2002 Jul 18;347(3):161-712124404
Cites: Circulation. 2002 Jul 23;106(4):416-2212135939
Cites: N Engl J Med. 2002 Aug 1;347(5):305-1312151467
Cites: Eur J Heart Fail. 2002 Aug;4(4):403-1012167377
Cites: JAMA. 2002 Sep 11;288(10):1252-912215132
Cites: J Am Coll Cardiol. 2002 Sep 4;40(5):976-8212225726
Cites: Clin Nephrol. 2002 Jul;58 Suppl 1:S37-4512227725
Cites: Rev Cardiovasc Med. 2002;3 Suppl 3:S48-5412447162
Cites: Rev Cardiovasc Med. 2002 Spring;3(2):71-612447150
Cites: Am J Cardiol. 1995 Jun 15;75(17):1256-627778550
Cites: Int J Cardiol. 1995 Jun 30;50(2):89-947591335
Cites: Clin Cardiol. 1995 Jul;18(7):370-67554541
Cites: Am J Cardiol. 1995 Dec 1;76(16):1194-77484912
Cites: Am J Cardiol. 1995 Dec 1;76(16):1198-2017484913
Cites: JAMA. 1996 May 22-29;275(20):1557-628622246
Cites: Angiology. 1996 May;47(5):447-548644941
Cites: Nephron. 1996;73(1):122-38742982
Cites: Circulation. 1997 Jun 17;95(12):2643-519193433
Cites: Clin Pharmacol Ther. 1997 Aug;62(2):187-939284855
Cites: Circulation. 1997 Aug 19;96(4):1165-729286945
Cites: Am J Cardiol. 1997 Sep 15;80(6):736-409315579
Cites: Crit Care Med. 1997 Dec;25(12):1969-759403744
Cites: Lancet. 1998 Feb 7;351(9100):389-939482291
Cites: Drugs. 1998 Feb;55(2):165-729506239
Cites: J Card Fail. 1997 Dec;3(4):249-549547437
Cites: Circulation. 1998 May 19;97(19):1921-99609085
Cites: N Engl J Med. 1998 Jul 30;339(5):321-89682046
Cites: N Engl J Med. 1998 Aug 6;339(6):387-959691107
Cites: Obes Surg. 1997 Jun;7(3):184-89730546
Cites: J Am Coll Cardiol. 1998 Sep;32(3):840-649741535
Cites: Lancet. 1998 Sep 12;352(9131):837-539742976
Cites: Lancet. 2003 May 31;361(9372):1843-812788569
Cites: Eur Heart J. 2001 Sep;22(17):1527-6011492984
Cites: Am J Cardiol. 1999 Oct 15;84(8):955-6, A810532524
Cites: Chest. 1999 Oct;116(4):1085-9110531176
Cites: Postgrad Med J. 1999 May;75(883):275-710533630
Cites: BMJ. 2000 Jan 22;320(7229):220-410642232
Cites: Lancet. 2000 Jan 22;355(9200):253-910675071
Cites: Lancet. 2000 Apr 1;355(9210):1126-3010791374
Cites: Eur J Emerg Med. 2000 Mar;7(1):15-2410839374
Cites: Circulation. 2000 Jul 11;102(2):203-1010889132
Cites: BMJ. 2000 Jul 22;321(7255):215-810903655
Cites: J Heart Lung Transplant. 2000 Jul;19(7):644-5210930813
Cites: Diabetes Care. 2003 Aug;26(8):2433-4112882875
Cites: ASAIO J. 2003 Jul-Aug;49(4):475-912918594
Cites: Lancet. 2003 Sep 6;362(9386):777-8113678871
Cites: Eur Heart J. 2003 Oct;24(19):1710-814522565
Cites: Eur Heart J. 2003 Oct;24(19):1735-4314522568
Cites: Lancet. 2003 Nov 8;362(9395):1527-3514615107
Cites: JAMA. 2003 Nov 19;290(19):2581-714625335
Cites: J Am Coll Cardiol. 2003 Nov 19;42(10):1793-80014642690
Cites: Circulation. 2002 Dec 10;106(24):3068-7212473553
Cites: Nephrol Dial Transplant. 2003 Jan;18(1):141-612480972
Cites: N Engl J Med. 2003 Jan 2;348(1):5-1412510037
Cites: JAMA. 2003 Jan 8;289(2):194-20212517230
Cites: J Am Coll Cardiol. 2003 Jan 15;41(2):204-1012535809
Cites: Circulation. 2003 Jan 21;107(2):294-912538431
Cites: Eur Heart J. 2003 Jan;24(1):28-6612559937
Cites: Eur Heart J. 2003 Feb;24(4):320-812581679
Cites: Diabetes Care. 2003 Mar;26(3):855-6012610049
Cites: Am J Kidney Dis. 2003 Mar;41(3):571-912612980
Cites: Circulation. 2003 Mar 11;107(9):1278-8312628948
Cites: Circulation. 2003 Mar 11;107(9):1284-9012628949
Cites: Eur J Heart Fail. 2003 Mar;5(2):155-6012644005
Cites: J Am Coll Cardiol. 2003 Mar 19;41(6):997-100312651048
Cites: Am Heart J. 2003 Mar;145(3):459-6612660669
Cites: Lancet. 2003 Mar 29;361(9363):1077-8312672310
Cites: Can J Cardiol. 2003 Mar 31;19(4):383-612704483
Cites: Can J Cardiol. 2003 Mar 31;19(4):439-4412704493
Cites: J Am Coll Cardiol. 2003 May 7;41(9):1452-712742280
Cites: J Hum Hypertens. 2003 Jun;17(6):419-2312764405
Cites: J Am Coll Cardiol. 2003 May 21;41(10):1797-80412767667
Cites: Ann Intern Med. 2003 Jun 3;138(11):907-1612779301
Cites: Heart Fail Monit. 2005;4(4):116-2216234898
Cites: Curr Heart Fail Rep. 2005 Dec;2(4):174-8216332310
Cites: Eur Heart J. 2006 Jan;27(2):178-8616339157
Cites: Eur J Heart Fail. 2006 Jan;8(1):105-1016387630
Cites: J Am Coll Cardiol. 2006 Jan 3;47(1):76-8416386668
Cites: J Am Coll Cardiol. 2006 Jan 3;47(1):91-716386670
Cites: Can J Cardiol. 2006 Jan;22(1):23-4516450016
Cites: Arch Intern Med. 2006 Feb 13;166(3):315-2016476871
Cites: J Am Coll Cardiol. 2006 Mar 21;47(6):1150-816545644
Cites: J Am Geriatr Soc. 2006 Mar;54(3):413-2016551307
Cites: Circulation. 2006 May 16;113(19):2335-6216702488
Cites: Arch Intern Med. 2006 May 22;166(10):1081-716717170
Cites: Eur J Heart Fail. 2006 Jun;8(4):390-916305826
Cites: J Am Coll Cardiol. 2006 Jun 20;47(12):2462-916781374
Cites: Cleve Clin J Med. 2006 Jun;73 Suppl 2:S8-13; discussion S30-316786907
Cites: Ann Thorac Surg. 2006 Jul;82(1):28-3316798182
Cites: N Engl J Med. 2006 Jul 20;355(3):251-916855265
Cites: N Engl J Med. 2006 Jul 20;355(3):260-916855266
Cites: Pharmacotherapy. 2006 Aug;26(8):1078-8516863484
Cites: Curr Heart Fail Rep. 2006 Jun;3(2):75-8016928340
Cites: Stroke. 2006 Sep;37(9):2220-4116917086
Cites: Can J Cardiol. 2006 Sep;22(11):913-2716971976
Cites: J Thorac Cardiovasc Surg. 2003 Nov;126(5):1634-514666044
Cites: Clin Chem. 2004 Jan;50(1):33-5014633912
Cites: J Am Coll Cardiol. 2004 Jan 7;43(1):61-714715185
Cites: N Engl J Med. 2004 Feb 12;350(7):647-5414960741
Cites: Heart. 2004 Mar;90(3):297-30314966052
Cites: Eur J Heart Fail. 2004 Mar 15;6(3):301-814987580
Cites: Eur J Heart Fail. 2004 Mar 15;6(3):343-5014987586
Cites: Eur J Heart Fail. 2004 Mar 15;6(3):359-6314987589
Cites: Eur Heart J. 2004 Mar;25(5):409-1515033253
Cites: J Am Coll Cardiol. 2004 Apr 21;43(8):1423-915093878
Cites: J Am Coll Cardiol. 2004 May 5;43(9):1534-4115120808
Cites: Lancet. 2004 May 29;363(9423):1751-615172772
PubMed ID
17245481 View in PubMed
Less detail

Chart review analysis of maternal factors and major malformations on Baffin Island 2000-2005

https://arctichealth.org/en/permalink/ahliterature257705
Source
Pages 191-192 and page 230 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Publication Type
Conference/Meeting Material
Date
2010
  1 document  
Author
Sy C
Cowan J
Sobol I
Osborne G
Arbour L
Author Affiliation
University of British Columbia
Nunavut Health and Social Services
Source
Pages 191-192 and page 230 in S. Chatwood, P. Orr and Tiina Ikaheimo, eds. Proceedings of the 14th International Congress on Circumpolar Health, Yellowknife, Canada, July 11-16, 2009. Securing the IPY Legacy: from Research to Action. International Journal of Circumpolar Health 2010; 69 (Suppl 7).
Date
2010
Language
English
Geographic Location
Canada
Publication Type
Conference/Meeting Material
Digital File Format
Text - PDF
Physical Holding
University of Alaska Anchorage
Keywords
Babies
Baffin Island
Birth defects
Canada
Heart defects
Inuit
Maternal factors
Mothers
Notes
Part of Abstracts: Oral Presentations. Chapter 4. Genetics, Population Genetics and Birth Defects in the North.
Part of Abstracts: Oral Presentations. Chapter 6. Maternal and Child Health.
Documents
Less detail

78 records – page 1 of 8.